BioAtla, Inc.
BCABNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $300,000 | — |
| Operating income | −$59.3M | −$73.9M | −$129.7M | −$108.1M | −$96.4M | −$30.1M |
| Net income | −$59.6M | −$69.8M | −$123.5M | −$106.5M | −$95.4M | −$35.9M |
| Total assets | $13.8M | $52.4M | $119.7M | $225.7M | $254.4M | $244.9M |
| Total liabilities | $50.0M | $38.2M | $49.0M | $45.4M | $43.6M | $35.0M |
| Equity | −$36.2M | $14.3M | $70.7M | $180.3M | $210.8M | $210.0M |
| EPS (diluted) | $-1.01 | $-1.44 | $-2.58 | $-2.74 | $-2.76 | — |
| Shares out. | 63.5M | 58.1M | 48.1M | 46.3M | 35.8M | 32.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 164.7%
- Return on assets
- −431.1%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 361.7%
- Debt / equity
- —
- Book value / share
- $-0.57
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -164.82distress
- Accruals / assets
- −82.5%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2025-03-19A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
- Phase 1Recruitingreadout ~2028-09-15Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Opoka Investment Fund CoPassive (13G)Oct 15, 2025
- Acorn Bioventures, L.P.Passive (13G)May 20, 2025
- Highbridge Capital Management LlcPassive (13G)Apr 25, 2025
- Short Jay M PhdPassive (13G)Feb 7, 2025
- Millennium Management LlcPassive (13G)Jan 24, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 162,567 | 5.5 | +10.4% |
| Apr 30, 2026 | 147,268 | 3.6 | +30.0% |
| Apr 15, 2026 | 113,264 | 1.6 | -95.2% |
| Mar 31, 2026 | 2.4M | 1.8 | +22.9% |
| Mar 13, 2026 | 1.9M | 1.3 | -5.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventApr 2, 2026
- Results of operations · Regulation FD disclosureMar 31, 2026
- Director / officer change · Shareholder voteMar 23, 2026
- Results of operations · Costs from exit or disposal · Director / officer change · Regulation FD disclosure · Other material eventMar 2, 2026
- Other material eventFeb 9, 2026
- Delisting / listing-standard notice · Regulation FD disclosureFeb 6, 2026
- Amended charter or bylaws · Shareholder vote · Regulation FD disclosure · Other material eventJan 30, 2026
- Unregistered equity sale · Amended charter or bylaws · Shareholder vote · Other material eventJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.